These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37777450)

  • 41. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.
    Srikantiah P; Vora P; Klugman KP
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
    Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.
    Robbins JM; Tilford JM; Jacobs RF; Wheeler JG; Gillaspy SR; Schutze GE
    Arch Pediatr Adolesc Med; 1998 Apr; 152(4):358-66. PubMed ID: 9559712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.
    Kim L; Rha B; Abramson JS; Anderson LJ; Byington CL; Chen GL; DeVincenzo J; Edwards KM; Englund JA; Falsey AR; Griffin MR; Karron RA; Martin KG; Meissner HC; Munoz FM; Pavia AT; Piedra PA; Schaffner W; Simões EAF; Singleton R; Talbot HK; Walsh EE; Zucker JR; Gerber SI
    Clin Infect Dis; 2017 Sep; 65(6):1020-1025. PubMed ID: 28903503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.
    Li Y; Johnson EK; Shi T; Campbell H; Chaves SS; Commaille-Chapus C; Dighero I; James SL; Mahé C; Ooi Y; Paget J; van Pomeren T; Viboud C; Nair H
    Lancet Respir Med; 2021 Feb; 9(2):175-185. PubMed ID: 32971018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
    Ginsberg GM; Somekh E; Schlesinger Y
    Isr J Health Policy Res; 2018 Dec; 7(1):63. PubMed ID: 30554570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina.
    Dvorkin J; Sosa E; Vodicka E; Baral R; Sancilio A; Dueñas K; Rodriguez A; Rojas-Roque C; Carruitero PB; Polack FP; Pecenka C; Libster R; Caballero MT
    BMC Public Health; 2024 Feb; 24(1):427. PubMed ID: 38336643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
    Amand C; Tong S; Kieffer A; Kyaw MH
    BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
    Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
    Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
    J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets.
    Reeves RM; van Wijhe M; Tong S; Lehtonen T; Stona L; Teirlinck AC; Fernandez LV; Li Y; Giaquinto C; Fischer TK; Demont C; Heikkinen T; Speltra I; van Boven M; Bøås H; Campbell H;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S599-S605. PubMed ID: 32815542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating the burden of adult hospitalized RSV infection using local and state data - methodology.
    Balasubramani GK; Nowalk MP; Eng H; Zimmerman RK
    Hum Vaccin Immunother; 2022 Dec; 18(1):1958610. PubMed ID: 35271432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The disease burden of respiratory syncytial virus in older adults.
    Kenmoe S; Nair H
    Curr Opin Infect Dis; 2024 Apr; 37(2):129-136. PubMed ID: 38197402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Respiratory Syncytial Virus Infection Among Hospitalized Infants in Four Middle-Income Countries.
    Biggs HM; Simões EAF; Abu Khader I; Thompson MG; Gordon A; Hunt DR; DeGroote NP; Porter RM; Bino S; Marar BI; Gresh L; de Jesus-Cornejo J; Langley G; Thornburg NJ; Peret TCT; Whitaker B; Zhang Y; Wang L; Patel MC; McMorrow M; Campbell W; Hasibra I; Duka E; Al-Gazo M; Kubale J; Sanchez F; Lucero MG; Tallo VL; Azziz-Baumgartner E; Simaku A; Gerber SI;
    J Pediatric Infect Dis Soc; 2023 Jul; 12(7):394-405. PubMed ID: 37313727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.